Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.62 |
| ▸ | SLC9A2 | Q9UBY0 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313733 | 0.91 | SLC9A1 (0.52) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL30142173 | 0.90 | SLC9A1 (0.51) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL6314722 | 0.90 | SLC9A1 (0.51) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL6313854 | 0.86 | ALDH1A1 (0.50) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL6313907 | 0.86 | ALDH1A1 (0.50) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL6311361 | 0.85 | SLC9A1 (0.65) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL6314818 | 0.84 | ALDH1A1 (0.48) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL6314019 | 0.84 | NPSR1 (0.49) | SLC9A1SLC9A2TP53POLBALDH1A1 | |
| SCHEMBL6313244 | 0.84 | MEN1 (0.56) | TP53POLBALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6321366 | 0.84 | NPC1 (0.46) | SLC9A1SLC9A2TP53POLBCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398983-B1 | POLYMER OF POLYIMIDE PRECURSOR, POSITIVE TYPE PHOTOSENSITIVE RESIN COMPOSITION, NEGATIVE TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC PARTS | SHINETSU CHEMICAL CO (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-11150556-B2 | Polymer of polyimide precursor, positive type photosensitive resin composition, negative type photosensitive resin composition, patterning process, method for forming cured film, interlayer insulating film, surface protective film, and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-10-19 | — | — | US | disclosed |
| EP-3398983-A1 | POLYMER OF POLYIMIDE PRECURSOR, POSITIVE TYPE PHOTOSENSITIVE RESIN COMPOSITION, NEGATIVE TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC PARTS | Shin-Etsu Chemical Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20180275513-A1 | POLYMER OF POLYIMIDE PRECURSOR, POSITIVE TYPE PHOTOSENSITIVE RESIN COMPOSITION, NEGATIVE TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC PARTS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-09-27 | — | — | US | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-6946233-B2 | High resolution; etching chemical resistance | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| US-20050142491-A1 | Novel epoxy compounds having an alicyclic structure, polymer compounds, resist materials, and patterning methods | HASEGAWA KOJI (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030054290-A1 | Polymer, resist material and patterning method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-03-20 | — | — | US | disclosed |
| US-20030050398-A1 | Novel epoxy compounds having an alicyclic structure, polymer compounds, resist materials, and patterning methods | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-03-13 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | SLC9A1 5/4885SLC9A2 12/4885TP53 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.